直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Federal Circuit Affirms Written Description Support, Vacates Mooted Non-Obviousness Finding

October 5, 2026

Authored and Edited by Joshua A. Sprague Oliveira; Christopher B. Anderson; Erik R. Puknys

In Exelixis, Inc., v. MSN Lab’ys Private LTD., No. 2025-1236 (Fed. Cir. Aug. 31, 2026), the Federal Circuit affirmed the district court’s validity findings regarding a group of asserted patents (the “Salt Patents”) and dismissed MSN’s appeal and vacated the underlying non-obviousness finding regarding the ’349 Patent.

Exelixis sued MSN for infringement of patents related to its kidney, liver, and differentiated thyroid cancer drug, Cabometyx®. In a bench trial, the district court found sufficient written description support for the asserted claims of the Salt Patents, to which MSN conceded infringement. The district court then found that the ’349 Patent was neither infringed nor invalid for obviousness. MSN appealed, challenging both validity findings. Exelixis cross-appealed as to the ’349 Patent noninfringement finding but later dismissed its cross-appeal, rendering this judgment of noninfringement final.

On appeal, the Federal Circuit affirmed the district court’s validity finding regarding the Salt Patents. It held that the district court properly found that disclosure of the claimed salt’s chemical name, formula, and crystalline structure provided adequate written description support as an identification of structural features possessed by members of the claimed genus.

Further, the Court found Exelixis’ dismissal of its cross-appeal mooted MSN’s challenge to the ’349 Patent validity finding and granted MSN’s motion to dismiss. The Federal Circuit then vacated the district court’s non-obviousness finding to avoid the “unfairness” of MSN’s inability to oppose this adverse judgment due to the prevailing party’s unilateral action—Exelixis’ dismissal of its cross-appeal.

Tags

prior art, Written description (35 USC § 112), Obviousness (35 USC § 103), standing

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Palo Alto, CA

Reston, VA

Washington, DC

Contacts

Joshua A. Sprague Oliveira
Associate
Washington, DC
+1 202 408 4487
Email
Christopher B. Anderson
Associate
Reston, VA
+1 571 203 2765
Email
Erik R. Puknys
Partner
Palo Alto, CA
+1 650 849 6644
Email

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Seminar

Global Innovation Index: Perspectives on IP and Innovation Ecosystems

December 14, 2026

Washington, DC

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Osaka

December 10, 2026

Osaka

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Tokyo

December 8, 2026

Tokyo

Workshop

Winning Global IP Disputes: Litigation, SEP, and FRAND Strategies

November 20, 2026

Shanghai

Reception

2026 National Veterans Legal Services Program Annual Benefit Reception

November 19, 2026

Washington, DC

Workshop

From Innovation to Commercialization: U.S. Patent Strategies, Licensing, and IP Transaction Best Practices

November 17, 2026

Beijing

Charitable

2026 ALYN Hospital Wheels of Love Ride

November 8-12, 2026

Northern District

Articles

An Introductory Guide to Patents for the U.S. Sports and Sports Tech Industry

November 3, 2026

INCONTESTABLE® Blog

Whose “Baby” Is the Logo? TTAB Says It Could Belong to Your Employer

November 3, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP